Longevity Science — 2026-04-24
This week in longevity science, the FDA cleared the first cellular rejuvenation trial for human testing — a landmark regulatory moment for the reprogramming field. Researchers at Altos Labs saw a notable departure as a leading scientist defected to the Buck Institute, signaling ongoing tensions between commercial and nonprofit aging research. Meanwhile, new clinical data continues to refine our understanding of rapamycin, tozorakimab, and early-stage senolytic compounds across multiple active trials.
Longevity Science — 2026-04-24
Top Research Findings
Nature Aging: Organelles as Metabolic Hubs in Longevity Regulation
Nature Aging's latest issue (updated this week) features a major review examining how organelles — including the endoplasmic reticulum, mitochondria, and lysosomes — act as metabolic signaling hubs in aging and longevity regulation. The review highlights the crosstalk between these organelles in maintaining cellular homeostasis and organism fitness, offering fresh mechanistic insight into why cellular maintenance declines with age and what therapeutic targets might emerge from this understanding. For human longevity science, mapping these organelle networks could guide a new generation of interventions beyond broad-spectrum mTOR inhibition.
AAMC: Can Aging Be Slowed? Academic Scientists Reassess Off-Label Prescribing
Published approximately one week ago, the Association of American Medical Colleges profiled new research from longevity clinics suggesting that human lifespan and healthspan could be extended through off-label prescribing of certain medications — including rapamycin and related compounds. The piece highlights a growing cohort of academic scientists who believe the evidence now justifies cautious clinical use, even before definitive trial readouts. This is relevant for readers considering whether to raise the topic with their physicians, as it reflects an emerging mainstream medical perspective rather than pure biohacker culture.
Seragon Study: SRN-901 Extends Median Lifespan in Mice
Listed this week on Longevity Technology's news feed, Seragon published preclinical data showing that their compound SRN-901 extends median lifespan in mice. While mouse lifespan data has historically not translated cleanly to humans, this adds to the pipeline of novel small molecules being evaluated by longevity-focused biotechs. The mechanism and target pathway have not yet been disclosed in public summaries, meaning the human relevance remains to be established. Watch for peer-reviewed publication in coming weeks.
BioAge Reports Positive Phase 1 Data for BGE-102
Also appearing this week on Longevity Technology, BioAge Labs reported positive Phase 1 clinical data for BGE-102, a compound in the company's aging-biology pipeline. Phase 1 data primarily assesses safety and tolerability rather than efficacy, but a clean safety profile is a prerequisite for advancing to larger trials that can test whether the drug actually slows aging-related decline. BioAge has previously used biomarker-driven approaches to identify drug targets based on human aging data.
Clinical Trials & Intervention Updates
Tozorakimab Meets Primary Endpoint in Phase III MIRANDA COPD Trial
Reported this week via Longevity Technology, tozorakimab — an anti-IL-33 antibody targeting inflammation — met its primary endpoint in the Phase III MIRANDA trial in COPD patients. This is significant for longevity medicine because COPD and chronic pulmonary inflammation are canonical age-related conditions, and anti-inflammatory biologics that demonstrate efficacy in late-stage trials could represent what Longevity Technology calls "inflammation's statin moment" — a reference to the transformative impact statins had on cardiovascular disease. If tozorakimab achieves regulatory approval, it would be one of the first biologics explicitly validated against an age-associated inflammatory condition at Phase III scale.
AlzeCure Completes Phase Ib Study of ACD856 (Alzheimer's Cognition Target)
AlzeCure Pharma completed its Phase Ib study of ACD856 this week, a compound designed to enhance neuronal signaling relevant to Alzheimer's and cognitive aging. Phase Ib completion means the dose-finding and early safety work is done, clearing the path to Phase II efficacy testing. Because cognitive decline is one of the most feared aspects of aging and current Alzheimer's therapies offer limited benefit, any compound that demonstrates Phase II efficacy in this area would be highly significant for healthspan — not just disease treatment.
NADMED Backs Cleveland Clinic Transplant Study on NAD+ Biology
Finnish diagnostics company NADMED announced backing for a Cleveland Clinic transplant study this week. The study is expected to examine NAD+ metabolism in transplant patients, providing human data on how NAD+ levels and biosynthesis behave under physiological stress. NADMED specializes in quantitative NAD+ measurement, and this collaboration with a major U.S. academic medical center adds clinical rigor to the NAD+ field — which has been largely driven by preclinical data and uncontrolled human studies. Results could clarify whether NAD+ supplementation is worth pursuing in higher-acuity patient populations.
Industry & Biotech Watch
FDA Clears First Cellular Rejuvenation Trial — Longevity Market Framed as $120B Opportunity
A press release distributed via Markets Business Insider (dated April 23, 2026) declares that the FDA has cleared what is described as the first cellular rejuvenation trial in humans, associated with Avaí Bio, Inc. (OTCQB: AVAI). The announcement frames the longevity sector as a $120 billion market. Cellular rejuvenation — based on partial reprogramming of aged cells toward a more youthful epigenetic state — has been one of the most discussed but least clinically tested areas in longevity science. FDA clearance to begin a human trial is a meaningful threshold, though early-phase trials will test safety first, not longevity extension per se. Readers should note that this press release originates from the company and has not yet been independently verified by peer-reviewed reporting.
Key Researcher Exits Bezos-Backed Altos Labs for Buck Institute
Reported on April 17, 2026, by San Francisco Business Times, a prominent researcher departed Altos Labs — the $3 billion rejuvenation startup backed by Jeff Bezos and Yuri Milner — to join the Buck Institute for Research on Aging, a nonprofit. The move reflects ongoing tension in the longevity field between fast-moving, well-funded commercial startups and mission-driven academic institutions. The Buck Institute has historically prioritized open science and publication; Altos Labs has been more secretive about its reprogramming research timelines. This kind of talent movement can shift where key discoveries are made — and how quickly they become public.
Mesoblast Invests in CAR Technology for Smarter Cell Therapies
Appearing this week on Longevity Technology, Mesoblast — a cell therapy biotech — announced an investment in CAR (chimeric antigen receptor) technology to advance smarter, more targeted cell-based therapies. Cell therapies are increasingly being explored for age-related inflammatory and degenerative conditions. Mesoblast's existing pipeline focuses on mesenchymal lineage cells that modulate inflammation; adding CAR engineering could significantly expand the precision of their approach for conditions like heart failure and graft-versus-host disease, both of which disproportionately affect older populations.
Deep Dive: Intervention Evidence Check — Ergothioneine
The Emerging Longevity Supplement You've Probably Never Heard Of
Ergothioneine is drawing fresh attention this week, with Longevity Technology publishing a dedicated feature on the molecule. Here's the current state of evidence:
What it is: Ergothioneine is a naturally occurring amino acid antioxidant found in mushrooms, black beans, and certain meats. It has a dedicated transporter in human cells (OCTN1/SLC22A4), suggesting evolutionary significance — cells actively accumulate it.
What the animal data shows: Ergothioneine supplementation has been associated with extended lifespan in invertebrate models and reduced oxidative stress markers in mammalian cell cultures. It appears to protect mitochondria, which are increasingly recognized as central to the aging process.
What human data exists: Observational studies have associated higher blood levels of ergothioneine with reduced risk of cardiovascular disease and cognitive decline in older adults. However, these are correlational — people who eat more mushrooms may differ from non-mushroom eaters in many other ways. No randomized controlled trial has yet tested ergothioneine supplementation against hard longevity outcomes in humans.
What's still speculative: Whether supplementing ergothioneine meaningfully raises tissue levels, whether raised tissue levels produce the protective effects seen in animal models, and whether any effect translates to actual healthspan or lifespan extension in people.
What readers should know: Ergothioneine is generally considered safe at dietary levels. Some supplements are now available, but the human evidence base is still observational and mechanistic, not interventional. It is worth watching, but premature to take specifically for longevity purposes without further trial data.
What to Watch Next
- Cellular Rejuvenation Trial Enrollment Details: With the FDA reportedly clearing Avaí Bio's cellular rejuvenation trial, watch for official trial registration on ClinicalTrials.gov and the first enrollment updates — these will reveal the actual design, patient population, and primary endpoints.
- Nature Aging Organelle Review Downstream Research: The new mechanistic framework linking ER-mitochondria-lysosome crosstalk to aging is likely to generate a wave of follow-up studies; watch for preprints on specific druggable targets within these pathways.
- MIRANDA Trial Regulatory Filing: Now that tozorakimab has met its Phase III primary endpoint in COPD, watch for an anticipated regulatory submission to the FDA or EMA — and whether the indication can be broadened to cover inflammaging more broadly.
- Insilico Medicine Longevity Board: Insilico Medicine announced formation of a longevity-specific board to oversee its AI-driven aging research this week. Their first public research priorities could signal where AI-accelerated drug discovery in aging is heading next.
Reader Action Items
-
Ask your doctor about the AAMC report on off-label longevity prescribing. The new AAMC coverage of longevity clinics using medications like rapamycin off-label reflects an important shift in mainstream medical thinking. If you are interested in longevity medicine, this is a good conversation starter — particularly for patients over 50 with no contraindications. The AAMC piece cites real clinical data, not just anecdote.
-
Follow the Avaí Bio cellular rejuvenation trial on ClinicalTrials.gov. Now that the FDA has reportedly cleared the first human cellular rejuvenation trial, tracking its registration and early results will be one of the most important things a longevity-interested reader can do in 2026. Search ClinicalTrials.gov for "cellular rejuvenation" or "partial reprogramming" to find the official record when it appears.
-
Add mushrooms to your diet. While ergothioneine supplement evidence is still early, dietary mushroom consumption is associated with higher circulating ergothioneine and a wide range of health benefits in observational data. It is one of the easiest, lowest-risk dietary changes you can make — and the evidence base is likely to grow.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
